Listerine, Tylenol Maker Kenvue Tops Estimates, Lifts Sales Outlook

0
302

Gabby Jones / Bloomberg via Getty Images

Shares of Kenvue (KVUE) rose in premarket trading Thursday after the maker of Band-Aid, Tylenol, and Listerine reported first-quarter results better than analysts’ estimates.

The former consumer-focused segment of Johnson & Johnson (JNJ) reported adjusted earnings per share of $0.24 on net sales of $3.74 billion. Both metrics declined from a year ago but by less than analysts polled by Visible Alpha had projected.

The consumer products maker said it now expects 2025 net sales growth of 1% to 3%, up from its prior forecast of between a 1% decline and a 1% increase. However, adjusted operating income margin is expected to decline rather than improve, “reflecting the estimated impact of tariffs,” while adjusted EPS is projected to be “about flat,” down from flat to a 2% increase.

Kenvue said it is “working to reduce the financial…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here